{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:49:29Z","timestamp":1695534569850},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,5,7]],"date-time":"2009-05-07T00:00:00Z","timestamp":1241654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2009,5,7]],"date-time":"2009-05-07T00:00:00Z","timestamp":1241654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s10637-009-9260-6","type":"journal-article","created":{"date-parts":[[2009,5,6]],"date-time":"2009-05-06T03:15:25Z","timestamp":1241579725000},"page":"171-177","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial"],"prefix":"10.1007","volume":"28","author":[{"given":"Sung Yong","family":"Oh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baek Yeol","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo Seop","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,7]]},"reference":[{"key":"9260_CR1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/ajh.20874","volume":"82","author":"SY Oh","year":"2007","unstructured":"Oh SY, Ryoo BY, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Kwon HC, Bang SM, Kim JH, Park J, Lee SS, Kim HY, Park K (2007) Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol 82:446\u2013452. doi:10.1002\/ajh.20874","journal-title":"Am J Hematol"},{"key":"9260_CR2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V95.3.802.003k19_802_806","volume":"95","author":"C Thieblemont","year":"2000","unstructured":"Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, Salles G, Coiffier B (2000) Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 95:802\u2013806","journal-title":"Blood"},{"key":"9260_CR3","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.1999.17.4.1254","volume":"17","author":"PL Zinzani","year":"1999","unstructured":"Zinzani PL, Magagnoli M, Galieni P, Martelli M, Poletti V, Zaja F, Molica S, Zaccaria A, Cantonetti AM, Gentilini P, Guardigni L, Gherlinzoni F, Ribersani M, Bendandi M, Albertini P, Tura S (1999) Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol 17:1254","journal-title":"J Clin Oncol"},{"key":"9260_CR4","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2002-04-1279","volume":"101","author":"E Zucca","year":"2003","unstructured":"Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, Patterson BJ, Ferreri AJ, Ponzoni M, Devizzi L, Giardini R, Pinotti G, Capella C, Zinzani PL, Pileri S, Lopez-Guillermo A, Campo E, Ambrosetti A, Baldini L, Cavalli F (2003) Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 101:2489\u20132495. doi:10.1182\/blood-2002-04-1279","journal-title":"Blood"},{"key":"9260_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.beha.2004.08.003","volume":"18","author":"PG Isaacson","year":"2005","unstructured":"Isaacson PG (2005) Update on MALT lymphomas. Best Pract Res Clin Haematol 18:57\u201368. doi:10.1016\/j.beha.2004.08.003","journal-title":"Best Pract Res Clin Haematol"},{"key":"9260_CR6","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/jnci\/djh102","volume":"96","author":"AJ Ferreri","year":"2004","unstructured":"Ferreri AJ, Guidoboni M, Ponzoni M, De Conciliis C, Dell\u2019Oro S, Fleischhauer K, Caggiari L, Lettini AA, Dal Cin E, Ieri R, Freschi M, Villa E, Boiocchi M, Dolcetti R (2004) Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 96:586\u2013594","journal-title":"J Natl Cancer Inst"},{"key":"9260_CR7","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/S0360-3016(03) 00767-3","volume":"57","author":"CY Fung","year":"2003","unstructured":"Fung CY, Tarbell NJ, Lucarelli MJ, Goldberg SI, Linggood RM, Harris NL, Ferry JA (2003) Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys 57:1382\u20131391. doi:10.1016\/S0360-3016(03)00767-3","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9260_CR8","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1200\/JCO.2003.06.085","volume":"21","author":"RW Tsang","year":"2003","unstructured":"Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, Crump M, Patterson BJ (2003) Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 21:4157\u20134164. doi:10.1200\/JCO.2003.06.085","journal-title":"J Clin Oncol"},{"key":"9260_CR9","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1158\/1078-0432.CCR-04-2282","volume":"11","author":"M Raderer","year":"2005","unstructured":"Raderer M, Streubel B, Woehrer S, Puespoek A, Jaeger U, Formanek M, Chott A (2005) High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res 11:3349\u20133352. doi:10.1158\/1078-0432.CCR-04-2282","journal-title":"Clin Cancer Res"},{"key":"9260_CR10","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1200\/JCO.1995.13.10.2524","volume":"13","author":"P Hammel","year":"1995","unstructured":"Hammel P, Haioun C, Chaumette MT, Gaulard P, Divine M, Reyes F, Delchier JC (1995) Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 13:2524\u20132529","journal-title":"J Clin Oncol"},{"key":"9260_CR11","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1200\/JCO.2002.05.117","volume":"20","author":"G Jager","year":"2002","unstructured":"Jager G, Neumeister P, Brezinschek R, Hinterleitner T, Fiebiger W, Penz M, Neumann HJ, Mlineritsch B, DeSantis M, Quehenberger F, Chott A, Beham-Schmid C, Hofler G, Linkesch W, Raderer M (2002) Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol 20:3872\u20133877. doi:10.1200\/JCO.2002.05.117","journal-title":"J Clin Oncol"},{"key":"9260_CR12","first-page":"47","volume":"22","author":"K Csoka","year":"1995","unstructured":"Csoka K, Liliemark J, Larsson R, Nygren P (1995) Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol 22:47\u201353","journal-title":"Semin Oncol"},{"key":"9260_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10549-007-9610-z","volume":"108","author":"S Dent","year":"2008","unstructured":"Dent S, Messersmith H, Trudeau M (2008) Gemcitabine in the management of metastatic breast cancer: a systematic review. Breast Cancer Res Treat 108:319\u2013331. doi:10.1007\/s10549-007-9610-z","journal-title":"Breast Cancer Res Treat"},{"key":"9260_CR14","doi-asserted-by":"publisher","unstructured":"Rivera F, Lopez-Tarruella S, Vega-Villegas MA, Salcedo M (2009) Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev. doi:10.1016\/j.ctrv.2008.11.007","DOI":"10.1016\/j.ctrv.2008.11.007"},{"key":"9260_CR15","first-page":"23S","volume":"20","author":"PA Bunn Jr","year":"2002","unstructured":"Bunn PA Jr (2002) Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 20:23S\u201333S","journal-title":"J Clin Oncol"},{"key":"9260_CR16","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2000.18.13.2615","volume":"18","author":"A Santoro","year":"2000","unstructured":"Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, Fiedler F, Parra HS, Benoehr C, Pacini M, Bonadonna G, Diehl V (2000) Gemcitabine in the treatment of refractory Hodgkin\u2019s disease: results of a multicenter phase II study. J Clin Oncol 18:2615\u20132619","journal-title":"J Clin Oncol"},{"key":"9260_CR17","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1200\/JCO.1999.17.12.3786","volume":"17","author":"A Fossa","year":"1999","unstructured":"Fossa A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, Bonadonna G, Seeber S, Nowrousian MR (1999) Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol 17:3786\u20133792","journal-title":"J Clin Oncol"},{"key":"9260_CR18","first-page":"926","volume":"85","author":"PL Zinzani","year":"2000","unstructured":"Zinzani PL, Bendandi M, Stefoni V, Albertini P, Gherlinzoni F, Tani M, Piccaluga PP, Tura S (2000) Value of gemcitabine treatment in heavily pretreated Hodgkin\u2019s disease patients. Haematologica 85:926\u2013929","journal-title":"Haematologica"},{"key":"9260_CR19","first-page":"1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored Int Working Group J Clin Oncol 17:1244","journal-title":"NCI Sponsored Int Working Group J Clin Oncol"},{"key":"9260_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1532\/IJH97.04050","volume":"79","author":"JO Armitage","year":"2004","unstructured":"Armitage JO, Tobinai K, Hoelzer D, Rummel MJ (2004) Treatment of indolent non-Hodgkin\u2019s lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. Int J Hematol 79:311\u2013321. doi:10.1532\/IJH97.04050","journal-title":"Int J Hematol"},{"key":"9260_CR21","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/cncr.20237","volume":"100","author":"PL Zinzani","year":"2004","unstructured":"Zinzani PL, Stefoni V, Musuraca G, Tani M, Alinari L, Gabriele A, Marchi E, Pileri S, Baccarani M (2004) Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer 100:2190\u20132194. doi:10.1002\/cncr.20237","journal-title":"Cancer"},{"key":"9260_CR22","doi-asserted-by":"publisher","first-page":"8442","DOI":"10.1200\/JCO.2004.00.8532","volume":"23","author":"M Raderer","year":"2005","unstructured":"Raderer M, Wohrer S, Bartsch R, Prager G, Drach J, Hejna M, Gaiger A, Turetschek K, Jaeger U, Streubel B, Zielinski CC (2005) Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 23:8442\u20138446. doi:10.1200\/JCO.2004.00.8532","journal-title":"J Clin Oncol"},{"key":"9260_CR23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/10428190801911704","volume":"49","author":"Y Oki","year":"2008","unstructured":"Oki Y, Younes A (2008) Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymphoma 49:883\u2013889. doi:10.1080\/10428190801911704","journal-title":"Leuk Lymphoma"},{"key":"9260_CR24","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1002\/cncr.23915","volume":"113","author":"SR Pasricha","year":"2008","unstructured":"Pasricha SR, Grigg A, Catalano J, Leahy M, Underhill C, Arthur C, D\u2019Rozario J, Lowenthal R, Reed K, Spencer A (2008) A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma. Cancer 113:3192\u20133198. doi:10.1002\/cncr.23915","journal-title":"Cancer"},{"issue":"Suppl 4","key":"9260_CR25","doi-asserted-by":"publisher","first-page":"iv18","DOI":"10.1093\/annonc\/mdj994","volume":"17","author":"G Corazzelli","year":"2006","unstructured":"Corazzelli G, Russo F, Capobianco G, Marcacci G, Della Cioppa P, Pinto A (2006) Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive\/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin\u2019s lymphoma: results of a pilot study. Ann Oncol 17(Suppl 4):iv18\u2013iv24. doi:10.1093\/annonc\/mdj994","journal-title":"Ann Oncol"},{"key":"9260_CR26","doi-asserted-by":"crossref","unstructured":"Corazzelli G, Capobianco G, Arcamone M, Ballerini PF, Iannitto E, Russo F, Frigeri F, Becchimanzi C, Marcacci G, De Chiara A, Pinto A (2009) Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory\/relapsing B-cell lymphoma. Cancer Chemother Pharmacol","DOI":"10.1007\/s00280-009-0941-9"},{"key":"9260_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1600-0609.2007.00996.x","volume":"80","author":"A Lopez","year":"2008","unstructured":"Lopez A, Gutierrez A, Palacios A, Blancas I, Navarrete M, Morey M, Perello A, Alarcon J, Martinez J, Rodriguez J (2008) GEMOX-R regimen is a highly effective salvage regimen in patients with refractory\/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 80:127\u2013132","journal-title":"Eur J Haematol"},{"key":"9260_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/10245330701214095","volume":"12","author":"B Sirohi","year":"2007","unstructured":"Sirohi B, Cunningham D, Norman A, Last K, Chau I, Horwich A, Oates J, Chong G, Wotherspoon A (2007) Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL). Hematology 12:149\u2013153. doi:10.1080\/10245330701214095","journal-title":"Hematology"},{"key":"9260_CR29","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/cncr.20587","volume":"101","author":"M Crump","year":"2004","unstructured":"Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R (2004) Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 101:1835\u20131842. doi:10.1002\/cncr.20587","journal-title":"Cancer"},{"key":"9260_CR30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/01.coc.0000143015.66143.22","volume":"28","author":"BJ Larson","year":"2005","unstructured":"Larson BJ, Waples JM, Pusateri A, Mendenhall NP, Lynch JW Jr (2005) A phase II study of gemcitabine in patients with relapsed or refractory low-grade non-Hodgkin lymphoma. Am J Clin Oncol 28:165\u2013168. doi:10.1097\/01.coc.0000143015.66143.22","journal-title":"Am J Clin Oncol"},{"key":"9260_CR31","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1046\/j.1365-2141.2001.02795.x","volume":"113","author":"C Dumontet","year":"2001","unstructured":"Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, Bourgeois E, Thieblemont C, Leleu X, Hequet O, Salles G, Coiffier B (2001) Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin\u2019s lymphoma. Br J Haematol 113:772\u2013778. doi:10.1046\/j.1365-2141.2001.02795.x","journal-title":"Br J Haematol"},{"key":"9260_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/01.coc.0000144812.74663.d0","volume":"28","author":"KN Ganjoo","year":"2005","unstructured":"Ganjoo KN, Robertson MJ, Fisher W, Jung SH, McClean J, Huh SY, Bufill J, Williams S, Cripe LD (2005) A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study. Am J Clin Oncol 28:169\u2013172. doi:10.1097\/01.coc.0000144812.74663.d0","journal-title":"Am J Clin Oncol"},{"key":"9260_CR33","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/0-306-46843-3_56","volume":"486","author":"CL van der Wilt","year":"2000","unstructured":"van der Wilt CL, Kroep JR, Bergman AM, Loves WJ, Alvarez E, Talianidis I, Eriksson S, van Groeningen CJ, Pinedo HM, Peters GJ (2000) The role of deoxycytidine kinase in gemcitabine cytotoxicity. Adv Exp Med Biol 486:287\u2013290. doi:10.1007\/0-306-46843-3_56","journal-title":"Adv Exp Med Biol"},{"key":"9260_CR34","first-page":"4138","volume":"54","author":"VW Ruiz van Haperen","year":"1994","unstructured":"Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM, Peters GJ (1994) Development and molecular characterization of a 2\u2032, 2\u2032-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 54:4138\u20134143","journal-title":"Cancer Res"},{"key":"9260_CR35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1046\/j.1365-2141.1999.01509.x","volume":"106","author":"C Dumontet","year":"1999","unstructured":"Dumontet C, Fabianowska-Majewska K, Mantincic D, Callet Bauchu E, Tigaud I, Gandhi V, Lepoivre M, Peters GJ, Rolland MO, Wyczechowska D, Fang X, Gazzo S, Voorn DA, Vanier-Viornery A, MacKey J (1999) Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 106:78\u201385. doi:10.1046\/j.1365-2141.1999.01509.x","journal-title":"Br J Haematol"},{"key":"9260_CR36","first-page":"4349","volume":"58","author":"JR Mackey","year":"1998","unstructured":"Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass CE (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58:4349\u20134357","journal-title":"Cancer Res"},{"key":"9260_CR37","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/S0959-8049(00)00246-X","volume":"36","author":"AM Bergman","year":"2000","unstructured":"Bergman AM, Giaccone G, van Moorsel CJ, Mauritz R, Noordhuis P, Pinedo HM, Peters GJ (2000) Cross-resistance in the 2\u2032, 2\u2032-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Eur J Cancer 36:1974\u20131983. doi:10.1016\/S0959-8049(00)00246-X","journal-title":"Eur J Cancer"},{"key":"9260_CR38","first-page":"1223","volume":"26","author":"M Schirmer","year":"1998","unstructured":"Schirmer M, Stegmann AP, Geisen F, Konwalinka G (1998) Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5\u2032-nucleotidase activity. Exp Hematol 26:1223\u20131228","journal-title":"Exp Hematol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-009-9260-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9260-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:34:59Z","timestamp":1678509299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-009-9260-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,7]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["9260"],"URL":"https:\/\/doi.org\/10.1007\/s10637-009-9260-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,7]]},"assertion":[{"value":"23 March 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}